LETTER TO THE EDITOR



The authors reply: Re: Yamamoto R, Sugiura T, Ashida R, Ohgi K, Yamada M, Otsuka S, and Uesaka K. Prognostic value of carbohydrate antigen 19-9 and the surgical margin in extrahepatic Cholangiocarcinoma. *Ann Gastroenterol Surg.* 2022;6:307–315

Dear Editor,

We would like to respond to the Letter to the Editor by Zaleskis et al., which comments on our original article "Prognostic value of carbohydrate antigen 19-9 and the surgical margin in extrahepatic cholangiocarcinoma" in *Ann Gastroenterol Surg*. They proposed using the specific growth rate (SGR) of the perioperative carbohydrate antigen 19-9 (CA19-9) values rather than the absolute value of CA19-9 for predicting the prognosis of extrahepatic cholangiocarcinoma.

We calculated the SGR of the perioperative CA19-9 values as follows: SGR = In(postoperativeCA19-9/preoperativeCA19-9)/interval days. The median SGR of CA19-9 was -0.020 with an interquartile range from -0.040 to -0.005. We divided the SGR values into four groups: group A (SGR < -0.06), group B (SGR ≥ -0.06 to <-0.03), group C (SGR ≥ -0.03 to <0), and group D (SGR ≥ 0). Table 1 shows the characteristics according to the SGR value. The preoperative CA19-9 value was significantly higher in group A and lower in group D in comparison to the other groups. The postoperative CA19-9 was significantly higher in group D in comparison to the other groups.

The R1 resection rate and locoregional recurrence rate did not differ to a statistically significant extent among the groups. The distant recurrence rate in group C was significantly lower in comparison to groups A and B. The overall survival of the groups did not differ to a statistically significant extent (Figure S1).

In contrast to Zaleskis's expectation, the SGR value of the perioperative CA19-9 values was not associated with the prognosis of extrahepatic cholangiocarcinoma. The SGR has a greater negative value when the perioperative CA19-9 reduction rate was greater. Patients with greater negative SGR values had higher preoperative CA19-9 values, so greater negative SGR values were not associated with a good prognosis. Group C had low preoperative and postoperative CA19-9 values, which might account for the lower rate of distant recurrence. On the other hand, an increase in the perioperative CA19-9 value results in a positive SGR value. Group D has positive SGR values, but the preoperative and postoperative CA19-9 values were not high; thus, positive SGR values were not associated with a poor prognosis.

TABLE 1 Characteristics according to the specific growth rate value

	Group A (n = 51)	Group B (n = 90)	Group C (n = 179)	Group D (n = 70)
Preoperative CA19-9 (U/mL) ^a	749 (307–1984)	105 (59-253)	24 (16-57)	13 (8-29)
Postoperative CA19-9 (U/mL) ^a	13 (7-37)	11 (6-20)	12 (8-20)	26 (15-72)
R1 resection	8 (16)	11 (12)	16 (9)	14 (20)
Locoregional recurrence	3 (6)	12 (13)	27 (15)	11 (16)
Distant recurrence	35 (69)	52 (58)	69 (39)	32 (46)
Overall survival (months) ^b	40 (31–57))	39 (32–59)	54 (45-82)	42 (33-78)

Note: Values in parentheses are percentages unless otherwise indicated.

Abbreviation: CA19-9, carbohydrate antigen 19-9.

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

© 2023 The Authors. Annals of Gastroenterological Surgery published by John Wiley & Sons Australia, Ltd on behalf of The Japanese Society of Gastroenterological Surgery.

^aValues are median (interquartile range).

^bValues are median (95% confidence interval).

The SGR value of the perioperative CA19-9 value was not related to the prognosis of extrahepatic cholangiocarcinoma. As we showed in our original article, the assessment of the absolute value of CA19-9 is important for predicting the prognosis of extrahepatic cholangiocarcinoma.³

FUNDING INFORMATION

No funding.

CONFLICT OF INTEREST STATEMENT

The authors declare no conflicts of interest for this article.

ETHICAL APPROVAL

Approval of the research protocol: N/A.

Informed Consent: N/A.

Registry and the Registration No. of the study/trial: N/A.

Animal Studies: N/A.

Ryusei Yamamoto
Teiichi Sugiura
Ryo Ashida
Katsuhisa Ohgi
Mihoko Yamada
Shimpei Otsuka
Katsuhiko Uesaka

Division of Hepato-Biliary-Pancreatic Surgery, Shizuoka Cancer Center, Shizuoka, Japan

Correspondence

Teiichi Sugiura, Division of Hepato-Biliary-Pancreatic Surgery, Shizuoka Cancer Center, 1007 Shimo-Nagakubo, Sunto-Nagaizumi, Shizuoka 411-8777, Japan.

Email: t.sugiura@scchr.jp

ORCID

Teiichi Sugiura https://orcid.org/0000-0001-7163-4084 Ryo Ashida https://orcid.org/0000-0001-8388-0135

REFERENCES

- Zaleskis G, Characiejus D, Šileikis A, Bosas P. Re: Yamamoto R, Sugiura T, Ashida R, Ohgi K, Yamada M, Otsuka S, and Uesaka K. Prognostic value of carbohydrate antigen 19-9 and the surgical margin in extrahepatic cholangiocarcinoma. *Ann Gastroenterol* Surg. 2022;6:307–315. Ann Gastroenterol Surg. 2023. https://doi. org/10.1002/ags3.12639
- 2. Mehrara E, Forssell-Aronsson E, Ahlman H, Bernhardt P. Specific growth rate versus doubling time for quantitative characterization of tumor growth rate. Cancer Res. 2007;67(8):3970–5.
- 3. Yamamoto R, Sugiura T, Ashida R, Ohgi K, Yamada M, Otsuka S, et al. Prognostic value of carbohydrate antigen 19-9 and the surgical margin in extrahepatic Cholangiocarcinoma. Ann Gastroenterol Surg. 2021;6(2):307–15.

SUPPORTING INFORMATION

Additional supporting information can be found online in the Supporting Information section at the end of this article.